# An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma

> **NCT01137006** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 27 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **BIOLOGICAL:** IMC-20D7S (Cohort 1A)
- **BIOLOGICAL:** IMC-20D7S (Cohort 2A)
- **BIOLOGICAL:** IMC-20D7S (Cohort 3A)
- **BIOLOGICAL:** IMC-20D7S (Cohort 4A)
- **BIOLOGICAL:** IMC-20D7S (Cohort 1B)
- **BIOLOGICAL:** IMC-20D7S (Cohort 2B)
- **BIOLOGICAL:** IMC-20D7S (Cohort 3B)

## Key facts

- **NCT ID:** NCT01137006
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2019-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01137006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01137006, "An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01137006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*